克唑替尼治疗结膜TFG::ROS1融合阳性炎性肌成纤维细胞瘤。

IF 1.3 4区 医学 Q3 OPHTHALMOLOGY
Liesl Bourdeaud'huy, Celine Jacobs, Ciel De Vriendt, Jo Van Dorpe, Dimitri Roels
{"title":"克唑替尼治疗结膜TFG::ROS1融合阳性炎性肌成纤维细胞瘤。","authors":"Liesl Bourdeaud'huy, Celine Jacobs, Ciel De Vriendt, Jo Van Dorpe, Dimitri Roels","doi":"10.1097/IOP.0000000000003035","DOIUrl":null,"url":null,"abstract":"<p><p>This case describes the clinical course and management of a conjunctival inflammatory myofibroblastic tumor with a transforming growth factor::ROS proto-oncogene 1 fusion in a 33-year-old woman presenting with a progressively enlarging subconjunctival mass. Diagnosis was confirmed by biopsy and RNA next-generation sequencing. Treatment with the tyrosine kinase inhibitor crizotinib led to complete tumor resolution; however, therapy was discontinued due to a sarcoid-like granulomatous reaction. Visual acuity remained stable at 20/20 throughout, and no recurrence was observed. This case highlights the diagnostic challenges of conjunctival inflammatory myofibroblastic tumor, the therapeutic potential of targeted kinase inhibition, and the critical role of genomic profiling in guiding personalized treatment for rare ocular tumors such as inflammatory myofibroblastic tumor.</p>","PeriodicalId":19588,"journal":{"name":"Ophthalmic Plastic and Reconstructive Surgery","volume":" ","pages":""},"PeriodicalIF":1.3000,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Conjunctival TFG::ROS1 Fusion Positive Inflammatory Myofibroblastic Tumor Treated With Crizotinib.\",\"authors\":\"Liesl Bourdeaud'huy, Celine Jacobs, Ciel De Vriendt, Jo Van Dorpe, Dimitri Roels\",\"doi\":\"10.1097/IOP.0000000000003035\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This case describes the clinical course and management of a conjunctival inflammatory myofibroblastic tumor with a transforming growth factor::ROS proto-oncogene 1 fusion in a 33-year-old woman presenting with a progressively enlarging subconjunctival mass. Diagnosis was confirmed by biopsy and RNA next-generation sequencing. Treatment with the tyrosine kinase inhibitor crizotinib led to complete tumor resolution; however, therapy was discontinued due to a sarcoid-like granulomatous reaction. Visual acuity remained stable at 20/20 throughout, and no recurrence was observed. This case highlights the diagnostic challenges of conjunctival inflammatory myofibroblastic tumor, the therapeutic potential of targeted kinase inhibition, and the critical role of genomic profiling in guiding personalized treatment for rare ocular tumors such as inflammatory myofibroblastic tumor.</p>\",\"PeriodicalId\":19588,\"journal\":{\"name\":\"Ophthalmic Plastic and Reconstructive Surgery\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-09-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ophthalmic Plastic and Reconstructive Surgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/IOP.0000000000003035\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmic Plastic and Reconstructive Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/IOP.0000000000003035","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

本病例描述了一名33岁女性结膜炎症性肌纤维母细胞肿瘤伴转化生长因子::ROS原癌基因1融合的临床过程和治疗方法,表现为结膜下肿物逐渐增大。通过活检和RNA新一代测序证实诊断。酪氨酸激酶抑制剂克唑替尼治疗导致肿瘤完全消退;然而,由于结节样肉芽肿反应而停止治疗。视力始终稳定在20/20,未见复发。该病例强调了结膜炎症性肌纤维母细胞瘤的诊断挑战,靶向激酶抑制的治疗潜力,以及基因组图谱在指导炎症性肌纤维母细胞瘤等罕见眼部肿瘤个性化治疗中的关键作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Conjunctival TFG::ROS1 Fusion Positive Inflammatory Myofibroblastic Tumor Treated With Crizotinib.

This case describes the clinical course and management of a conjunctival inflammatory myofibroblastic tumor with a transforming growth factor::ROS proto-oncogene 1 fusion in a 33-year-old woman presenting with a progressively enlarging subconjunctival mass. Diagnosis was confirmed by biopsy and RNA next-generation sequencing. Treatment with the tyrosine kinase inhibitor crizotinib led to complete tumor resolution; however, therapy was discontinued due to a sarcoid-like granulomatous reaction. Visual acuity remained stable at 20/20 throughout, and no recurrence was observed. This case highlights the diagnostic challenges of conjunctival inflammatory myofibroblastic tumor, the therapeutic potential of targeted kinase inhibition, and the critical role of genomic profiling in guiding personalized treatment for rare ocular tumors such as inflammatory myofibroblastic tumor.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.50
自引率
10.00%
发文量
322
审稿时长
3-8 weeks
期刊介绍: Ophthalmic Plastic and Reconstructive Surgery features original articles and reviews on topics such as ptosis, eyelid reconstruction, orbital diagnosis and surgery, lacrimal problems, and eyelid malposition. Update reports on diagnostic techniques, surgical equipment and instrumentation, and medical therapies are included, as well as detailed analyses of recent research findings and their clinical applications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信